“…However, in the current study, the results of the univariate analysis revealed that the grade of HFSR was not a predictive factor for tumor response to sorafenib. Compared with the TARGET study (4), our data indicated that the skin toxicity including HFSR in Chinese patients was much more frequent (60 vs. 33%) and more severe (26.7 vs. 6% with grade ≥3), as in the case of previous data obtained from Asia (11)(12)(13)22), and the resultant dose reduction may conceal the relevance between the grade of HFSR and the tumor response to sorafenib. A possible reason for the significant differences in the incidence of HFSR may include the difference in body surface area.…”